Six patients with the acquired immune deficiency syndrome (AIDS) had exacerbations or recurrences ofpreviously quiescent atopic disease when they developed immunodeficiency. Four developed a different atopic illness from that suffered previously. Atopic symptoms developed within three months after the patients developed AIDS or during prodromal illness. Two ofthe patients were treated with recombinant interferon gamma: both showed a string improvement in symptoms and cellular immunity.
Introduction
The mechanisms underlying induction and control of the allergic response in man are incompletely understood. The observation of a recrudescence of previously quiescent atopic disease in adults with the acquired immune deficiency syndrome (AIDS) prompted a study of its pathogenesis; in two of the patients we assessed the effect of giving interferon gamma.
Patients, methods, and results
A history ofallergic disease was sought in 16 consecutive patients in whom AIDS was diagnosed and in one patient seen previously. Prick testing for immediate hypersensitivity was performed by standard methods with 16 common allergens and for delayed hypersensitivity with three standard antigens. Total serum IgE concentrations were measured with a paper radioimmunosorbent test (Prist, Pharmacia). Lymphocyte subsets and lymphokine production were also estimated. ' Seven patients had a history of atopic disease (asthma, eczema, or hay fever) in childhood or adolescence (table); in one this had persisted into adult life. In the five patients who had "grown out of' their allergies, atopic symptoms recurred when they became immunodeficient. In a further patient atopic symptoms increased at this time. None of the 10 patients without previous atopic disease developed atopic symptoms within a year after the diagnosis of AIDS. There were no appreciable differences in age, time from diagnosis, or manifestations of AIDS between the two groups.
Two of the seven patients with atopy, but none of the others, had a family history ofatopy. Four ofthe six patients with a recurrence or exacerbation of symptoms developed a different atopic disorder from that suffered previously. Atopic symptoms occurred within three months after the patient developed AIDS or during prodromal illness, when they were temporally associated with signs of early immunodeficiency-that is, chronic mucocutaneous herpes simplex or candidiasis, or both.
The patients with atopy had evidence of increased type I hypersensitivity with more positive results on prick testing (mean 9, range 6-12) than the others (mean 2, range 0-4). There were no significant differences between the two groups in IgE concentrations (mean 158-2 kU/I in atopic patients compared with 200-6 kU/I in the others) or in T4 (CD4) cell counts or delayed type hypersensitivity responses.
Two patients showed striking improvement in their atopic symptoms during a trial of recombinant interferon gamma (Immuneron; Biogen, Geneva); they received twice weekly intravenous infusions of 5 1 x107 units/m2 (case 2) and 1 7x 105 units/M2 (case 5) for eight weeks. One patient (case 2) had developed angio-oedema after ingesting milk: mucosal swelling occurred within five to 10 minutes, even after diluted milk; after eight weeks' treatment she tolerated undiluted milk without symptoms. The other patient had asthma needing daily inhaled salbutamol. After four weeks' treatment this had resolved, and he remained asymptomatic. His asthma gradually returned four weeks after he stopped taking interferon gamma but resolved on reintroduction of the drug. Both patients had concomitant immunological improvement during treatment, shown by (1) conversion of one third of previously negative tests of delayed type hypersensitivity; (2) increase in T4 lymphocytes (0-26 to 0-43x 109/1 and 0-48 to 0-77x 109/1); (3) production ofinterferon gamma (and interleukin 2 in case 5) by unstimulated and mitogen stimulated lymphocytes (previously absent); and (4) This study provided striking evidence for the in vivo activity of recombinant interferon gamma. Improvement in the atopic symptoms may have been caused by a direct effect of interferon gamma on mediation of the allergic response-for example, by influencing the cellular control ofIgE production or by a peripheral effect on mast cell binding of or responsiveness to IgE.
Although an increased incidence ofatopic eczema has been noted in children with AIDS,4 this is the first documentation of exacerbation of atopy in adults. We have provided evidence that cellular immunity, apparently through interferon gamma, has a role in regulating atopy; this has implications for the pathogenetic mechanisms underlying atopic disease in general.
